BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) Appoints Biotechnology Veteran John Chiplin, Ph.D. to Board of Directors


1/8/2013 9:15:07 AM

SAN DIEGO, CA--(Marketwire - January 08, 2013) - Medistem Inc. (PINKSHEETS: MEDS), announced today that John Chiplin, Ph.D., has been elected to its Board of Directors. Dr. Chiplin has over 25 years of experience as a biopharmaceutical executive and is currently CEO of Polynoma, a Phase III cancer vaccine company. Dr. Chiplin is also on the Board of Directors of Benitec, an RNA interference company with which Medistem has authored two peer-reviewed scientific publications. Dr. Chiplin's appointment expands the number of Medistem board members to six.

"To my knowledge Medistem is the only company in the history of cell therapy to take a cell from discovery to FDA clearance and clinical trials in the span of 4 years," said Dr. Chiplin. "I believe Medistem has an outstanding management team and have watched with great interest the company's evolution. I believe the company is well positioned to transform the stem cell industry and I look forward to helping shape the company's future as a member of the board."

Dr. Chiplin has broad-based experience in the life science and technology industries in both leadership and investment roles. Prior to Polynoma, Dr. Chiplin was founding CEO of Arana Therapeutics, a new generation antibody developer and a board member of Domantis, Inc., prior to the acquisition of these companies by Cephalon ($329 million) and GSK ($458 million), respectively. Prior to founding Arana, Dr. Chiplin was Managing Director of U.K. based ITI Life Sciences investment Fund. Dr. Chiplin holds Pharmacy and Doctoral degrees from the University of Nottingham, UK.

"We are delighted to have John join our board. The combination of scientific and business acumen, as well as practical knowledge of biotherapeutic development that John possesses is an extremely rare combination," said Alan Lewis, Ph.D., CEO of Medistem. "John has been involved in several successful exits, we are looking forward to synergizing with his talents at optimizing the value of our universal donor stem cell product."

About Medistem Inc.

Medistem Inc., is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Medistem Inc. These can be identified by the use of forward-looking words, such as "believes," "expects," "may," "intends," "anticipates," "plans," "estimates," or any other analogous or similar expressions intended to identify forward-looking statements. These forward-looking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this presentation will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


Contact:
Thomas Ichim, Ph.D
President and Chief Scientific Officer
Medistem Inc.
9255 Towne Centre Drive
Suite 450
San Diego
CA 92122
858 349 3617
www.medisteminc.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->